4basebio (LON:4BB) Issues Earnings Results

Key Points

• 4basebio reported earnings of GBX 50 per share for the quarter, indicating a financial performance update.
• The company's stock price decreased by 1.1% to open at GBX 722, with a market capitalization of £111.80 million.
• 4basebio specializes in providing therapeutic synthetic DNA for gene therapies and aims to develop high-quality, GMP grade synthetic DNA to enhance patient delivery systems.

4basebio (LON:4BB - ) announced its quarterly earnings data on Monday. The company reported GBX (50) earnings per share for the quarter, Digital Look Earnings reports.

4basebio Stock Down 1.1%

Shares of LON:4BB opened at GBX 722 on Tuesday. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The company has a market capitalization of £111.80 million, a price-to-earnings ratio of -768.09 and a beta of 1.09. The business has a 50-day moving average price of GBX 884.80 and a 200 day moving average price of GBX 1,016.05. 4basebio has a 12-month low of GBX 704.50 and a 12-month high of GBX 1,500.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.